In episode 51 of Hims House, Bayside returns to the podcast to for year-end recap + 2026 predictions. The conversation covers Hims & Hers’ eventful 2025—international expansion, acquisitions, new product categories, partnerships and breakups—before pivoting to what investors should watch for in 2026. Bayside, who shifted to a more cautious stance mid-2025, explains his current thinking on valuation, growth rates, and the catalysts that could change the narrative. The episode closes with bold predictions about tirzepatide, a potential Super Bowl ad, and where the stock might trade heading into earnings.

00:00 - Welcome back to Bayside

01:10 - 2025 Recap: Labs, testosterone, menopause, international, acquisitions (Livewell, YourBio), $250M buyback, Deb Autor as Chief Policy Officer

03:21 - Revenue concerns

08:45 - Valuation framework

11:30 - Is compounding still at risk?

16:51 - The competitive landscape

20:22 - Super Bowl Ad Speculation

24:15 - Tirzepatide?!

29:32 - Peptides Opportunity

32:13 - Novo partnership “active talks”

38:13 - 2026 predictions

45:30 - Wearables?

50:10 - Celebrity partnership gap

Get full access to Hims House at himshouse.substack.com/subscribe